JP2013515576A - 嚥下可能薬物送達デバイスおよび薬物送達方法 - Google Patents
嚥下可能薬物送達デバイスおよび薬物送達方法 Download PDFInfo
- Publication number
- JP2013515576A JP2013515576A JP2012546244A JP2012546244A JP2013515576A JP 2013515576 A JP2013515576 A JP 2013515576A JP 2012546244 A JP2012546244 A JP 2012546244A JP 2012546244 A JP2012546244 A JP 2012546244A JP 2013515576 A JP2013515576 A JP 2013515576A
- Authority
- JP
- Japan
- Prior art keywords
- tissue penetrating
- capsule
- therapeutic agent
- penetrating member
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 100
- 238000012377 drug delivery Methods 0.000 title claims description 59
- 239000003814 drug Substances 0.000 claims abstract description 507
- 230000000149 penetrating effect Effects 0.000 claims abstract description 380
- 229940079593 drug Drugs 0.000 claims abstract description 346
- 239000002775 capsule Substances 0.000 claims abstract description 293
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 161
- 230000000968 intestinal effect Effects 0.000 claims abstract description 144
- 230000007246 mechanism Effects 0.000 claims abstract description 127
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 124
- 238000002360 preparation method Methods 0.000 claims abstract description 85
- 210000000936 intestine Anatomy 0.000 claims abstract description 29
- 230000002496 gastric effect Effects 0.000 claims abstract description 8
- 210000000813 small intestine Anatomy 0.000 claims description 177
- 239000000463 material Substances 0.000 claims description 88
- 230000033001 locomotion Effects 0.000 claims description 72
- 239000007788 liquid Substances 0.000 claims description 62
- 230000008602 contraction Effects 0.000 claims description 45
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 43
- 238000002955 isolation Methods 0.000 claims description 39
- 239000000376 reactant Substances 0.000 claims description 35
- 239000000126 substance Substances 0.000 claims description 32
- 230000015556 catabolic process Effects 0.000 claims description 31
- 238000006731 degradation reaction Methods 0.000 claims description 31
- 239000012530 fluid Substances 0.000 claims description 31
- 230000002572 peristaltic effect Effects 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 28
- 239000008103 glucose Substances 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 25
- 230000004044 response Effects 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 24
- 102000004877 Insulin Human genes 0.000 claims description 22
- 230000002411 adverse Effects 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 22
- 229940125396 insulin Drugs 0.000 claims description 22
- 108090001061 Insulin Proteins 0.000 claims description 21
- 229920000642 polymer Polymers 0.000 claims description 20
- 238000000926 separation method Methods 0.000 claims description 20
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 17
- 108010011459 Exenatide Proteins 0.000 claims description 17
- 229960001519 exenatide Drugs 0.000 claims description 17
- 239000000859 incretin Substances 0.000 claims description 17
- 239000000122 growth hormone Substances 0.000 claims description 16
- 210000002784 stomach Anatomy 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- -1 arubyglutide Chemical compound 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 13
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 13
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 229960001319 parathyroid hormone Drugs 0.000 claims description 13
- 239000000199 parathyroid hormone Substances 0.000 claims description 13
- 229920002988 biodegradable polymer Polymers 0.000 claims description 12
- 239000004621 biodegradable polymer Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 230000009747 swallowing Effects 0.000 claims description 12
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims description 11
- 108010051696 Growth Hormone Proteins 0.000 claims description 11
- 102000018997 Growth Hormone Human genes 0.000 claims description 11
- 102000014150 Interferons Human genes 0.000 claims description 11
- 108010050904 Interferons Proteins 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims description 10
- 230000000717 retained effect Effects 0.000 claims description 10
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 229940123208 Biguanide Drugs 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 230000000573 anti-seizure effect Effects 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 7
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 7
- 238000002144 chemical decomposition reaction Methods 0.000 claims description 7
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 7
- 229960003883 furosemide Drugs 0.000 claims description 7
- 239000008188 pellet Substances 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 6
- 230000002641 glycemic effect Effects 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 230000013011 mating Effects 0.000 claims description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 229960003105 metformin Drugs 0.000 claims description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 108010019598 Liraglutide Proteins 0.000 claims description 4
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 4
- 230000000740 bleeding effect Effects 0.000 claims description 4
- 230000000593 degrading effect Effects 0.000 claims description 4
- 229960002701 liraglutide Drugs 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 3
- 230000002232 neuromuscular Effects 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004642 Polyimide Substances 0.000 claims description 2
- 208000024799 Thyroid disease Diseases 0.000 claims description 2
- 208000034158 bleeding Diseases 0.000 claims description 2
- 239000012830 cancer therapeutic Substances 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001721 polyimide Polymers 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 108010048573 taspoglutide Proteins 0.000 claims description 2
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 claims description 2
- 229950007151 taspoglutide Drugs 0.000 claims description 2
- 208000021510 thyroid gland disease Diseases 0.000 claims description 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims 2
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 2
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 claims 2
- 206010034133 Pathogen resistance Diseases 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 229960001031 glucose Drugs 0.000 claims 2
- 238000011287 therapeutic dose Methods 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000036961 partial effect Effects 0.000 claims 1
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 299
- 208000024891 symptom Diseases 0.000 description 33
- 239000000203 mixture Substances 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000006065 biodegradation reaction Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 238000013459 approach Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 210000002429 large intestine Anatomy 0.000 description 10
- 238000009826 distribution Methods 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 238000004132 cross linking Methods 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 238000000465 moulding Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000037213 diet Effects 0.000 description 7
- 230000001079 digestive effect Effects 0.000 description 7
- 230000035515 penetration Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 229940044683 chemotherapy drug Drugs 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229940124531 pharmaceutical excipient Drugs 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 5
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 229960003965 antiepileptics Drugs 0.000 description 5
- 230000002146 bilateral effect Effects 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 229940047124 interferons Drugs 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000003430 antimalarial agent Substances 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000001723 curing Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 239000002702 enteric coating Substances 0.000 description 4
- 238000009505 enteric coating Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000000935 solvent evaporation Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 239000003096 antiparasitic agent Substances 0.000 description 3
- 229940125687 antiparasitic agent Drugs 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229920006237 degradable polymer Polymers 0.000 description 3
- 238000002716 delivery method Methods 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000005979 thermal decomposition reaction Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940033495 antimalarials Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 229920005570 flexible polymer Polymers 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000005389 magnetism Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000010094 polymer processing Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 101710092928 Insulin-like peptide-1 Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241001637516 Polygonia c-album Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000009975 flexible effect Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940095884 glucophage Drugs 0.000 description 1
- 230000009546 growth abnormality Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000019692 hotdogs Nutrition 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000007996 nephrogenic syndrome of inappropriate antidiuresis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000449 pharmaceutical disintegrant Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/06—Devices, other than using radiation, for detecting or locating foreign bodies ; Determining position of diagnostic devices within or on the body of the patient
- A61B5/065—Determining position of the probe employing exclusively positioning means located on or in the probe, e.g. using position sensors arranged on the probe
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/07—Endoradiosondes
- A61B5/073—Intestinal transmitters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14539—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
- A61B5/4094—Diagnosing or monitoring seizure diseases, e.g. epilepsy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
- A61M2005/14284—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation with needle insertion means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Anesthesiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Human Computer Interaction (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Optics & Photonics (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28476609P | 2009-12-24 | 2009-12-24 | |
| US61/284,766 | 2009-12-24 | ||
| US34033110P | 2010-03-15 | 2010-03-15 | |
| US61/340,331 | 2010-03-15 | ||
| US39530410P | 2010-05-10 | 2010-05-10 | |
| US61/395,304 | 2010-05-10 | ||
| PCT/US2010/062070 WO2011079302A2 (en) | 2009-12-24 | 2010-12-23 | Swallowable drug delivery device and methods of drug delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015115816A Division JP2015186590A (ja) | 2009-12-24 | 2015-06-08 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013515576A true JP2013515576A (ja) | 2013-05-09 |
| JP2013515576A5 JP2013515576A5 (enExample) | 2014-02-20 |
Family
ID=44196421
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546244A Withdrawn JP2013515576A (ja) | 2009-12-24 | 2010-12-23 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2015115816A Withdrawn JP2015186590A (ja) | 2009-12-24 | 2015-06-08 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2016196141A Active JP6484208B2 (ja) | 2009-12-24 | 2016-10-04 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2018046568A Withdrawn JP2018110907A (ja) | 2009-12-24 | 2018-03-14 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2020002601A Active JP7590811B2 (ja) | 2009-12-24 | 2020-01-10 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2021072584A Active JP7616937B2 (ja) | 2009-12-24 | 2021-04-22 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2023092726A Withdrawn JP2023116591A (ja) | 2009-12-24 | 2023-06-05 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015115816A Withdrawn JP2015186590A (ja) | 2009-12-24 | 2015-06-08 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2016196141A Active JP6484208B2 (ja) | 2009-12-24 | 2016-10-04 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2018046568A Withdrawn JP2018110907A (ja) | 2009-12-24 | 2018-03-14 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2020002601A Active JP7590811B2 (ja) | 2009-12-24 | 2020-01-10 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2021072584A Active JP7616937B2 (ja) | 2009-12-24 | 2021-04-22 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
| JP2023092726A Withdrawn JP2023116591A (ja) | 2009-12-24 | 2023-06-05 | 嚥下可能薬物送達デバイスおよび薬物送達方法 |
Country Status (11)
| Country | Link |
|---|---|
| EP (4) | EP4056173B1 (enExample) |
| JP (7) | JP2013515576A (enExample) |
| CN (2) | CN102905753B (enExample) |
| AU (5) | AU2010336330B2 (enExample) |
| CA (1) | CA2785168C (enExample) |
| DK (3) | DK3756657T3 (enExample) |
| ES (2) | ES2804716T3 (enExample) |
| FI (1) | FI3756657T3 (enExample) |
| PL (2) | PL3756657T3 (enExample) |
| PT (1) | PT3756657T (enExample) |
| WO (1) | WO2011079302A2 (enExample) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013522194A (ja) * | 2010-03-10 | 2013-06-13 | インキューブ ラブズ， エルエルシー | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2016529066A (ja) * | 2013-09-05 | 2016-09-23 | ヴェリリー ライフ サイエンシズ エルエルシー | 機能化粒子の送達 |
| JP2017521479A (ja) * | 2014-05-15 | 2017-08-03 | ラニ セラピューティクス， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| JP2018520995A (ja) * | 2015-05-08 | 2018-08-02 | インキューブ ラブズ， エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤 |
| JP2018526403A (ja) * | 2015-09-08 | 2018-09-13 | インキューブ ラブズ， エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤 |
| JP2020520700A (ja) * | 2017-05-17 | 2020-07-16 | マサチューセッツ インスティテュート オブ テクノロジー | 自己復元システムならびに関連構成要素および方法 |
| CN112867483A (zh) * | 2018-08-14 | 2021-05-28 | 阿尔玛疗法有限公司 | 可膨胀的药物递送丸剂 |
| JP2021535090A (ja) * | 2018-08-15 | 2021-12-16 | リンドラ セラピューティクス， インコーポレイティド | 治療薬物の腸内送達のためのシステム |
| JP2022502383A (ja) * | 2018-09-25 | 2022-01-11 | ラニ セラピューティクス， エルエルシー | 拡張可能なエンクロージャを備えた摂取可能なデバイス |
| JP2022523532A (ja) * | 2019-03-01 | 2022-04-25 | ラニ セラピューティクス， エルエルシー | 治療剤を胃壁の中に送達するためのデバイス、システム、および方法 |
| JP2022535297A (ja) * | 2019-06-07 | 2022-08-05 | ノボ・ノルデイスク・エー／エス | 送達部材取り外しを有する摂取可能な装置 |
| JP2022552829A (ja) * | 2019-10-08 | 2022-12-20 | インキューブ ラブズ， エルエルシー | 徐放性製剤送達デバイス |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| WO2023002270A1 (en) * | 2021-07-19 | 2023-01-26 | Cochlear Limited | Self-propelled pharmaceutical delivery capsules |
| US11771829B2 (en) | 2019-02-01 | 2023-10-03 | Massachusetts Institute Of Technology | Systems and methods for liquid injection |
| US12018090B2 (en) | 2014-05-15 | 2024-06-25 | Rani Therapeutics, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US12121688B2 (en) | 2019-02-01 | 2024-10-22 | Novo Nordisk A/S | Medical device with actuation mechanism |
| JP2025081392A (ja) * | 2020-09-16 | 2025-05-27 | イーライ リリー アンド カンパニー | 拡張アームを有する経口薬物送達デバイス |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102770151B (zh) | 2009-08-03 | 2018-07-31 | 因卡伯实验室有限责任公司 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
| US8562589B2 (en) | 2009-12-24 | 2013-10-22 | Rani Therapeutics, Llc | Swallowable drug delivery device and method of delivery |
| AU2010336330B2 (en) | 2009-12-24 | 2016-04-28 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
| US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8764733B2 (en) | 2010-12-23 | 2014-07-01 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US9149617B2 (en) | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| NO3117865T3 (enExample) | 2011-01-21 | 2018-04-07 | ||
| PL3653223T3 (pl) | 2011-06-29 | 2021-12-20 | Rani Therapeutics, Llc | Urządzenie do doustnego dostarczania związków leczniczych |
| PL2726091T3 (pl) * | 2011-06-29 | 2020-08-10 | Rani Therapeutics, Llc | Preparaty lecznicze dostarczane do kanału przewodu jelitowego za pomocą połykalnego urządzenia dostarczającego lek |
| CA2901923C (en) * | 2013-03-15 | 2021-12-07 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
| CN103479401B (zh) * | 2013-09-29 | 2015-08-19 | 中山大学附属第一医院 | 一种肠道生物标志物采样器 |
| JP6666858B2 (ja) * | 2014-06-11 | 2020-03-18 | マサチューセッツ インスティテュート オブ テクノロジー | 滞留構造体および関連方法 |
| WO2016155671A1 (zh) * | 2015-04-02 | 2016-10-06 | 傅君志 | 可吞咽式装置 |
| EP3426263A4 (en) * | 2016-03-09 | 2019-10-16 | Incube Labs, LLC | METHOD AND ARTICLE FOR THE DELIVERY OF LIVABLE CELLS IN SOLID TISSUE |
| US20180070857A1 (en) | 2016-09-09 | 2018-03-15 | Progenity Inc. | Electromechanical ingestible device for delivery of a dispensable substance |
| FR3059553B1 (fr) * | 2016-12-07 | 2021-04-23 | Univ Grenoble Alpes | Dispositif implantable |
| CA3046023A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| CN107050578A (zh) * | 2017-05-04 | 2017-08-18 | 梁曦 | 一种药物自动注射装置 |
| IL270674B2 (en) * | 2017-05-19 | 2024-12-01 | Shalon Tidhar | Instruments and methods for collecting samples from the digestive system |
| CN115844361A (zh) * | 2017-06-12 | 2023-03-28 | 拉尼医疗有限公司 | 用于测定胃排空参数的可吞咽胶囊、系统和方法 |
| CN108324231A (zh) * | 2018-03-14 | 2018-07-27 | 潍坊学院 | 一种自清洁上药胶囊内镜 |
| SG11202009767PA (en) | 2018-04-10 | 2020-10-29 | Panacea Biomatx Inc | Method and system for making personalized nutritional and pharmaceutical formulations using additive manufacturing |
| US12128201B2 (en) | 2018-08-23 | 2024-10-29 | Baywind Bioventures | Capsule device for delivery of active agent to gastrointestinal tract |
| CN116726362A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| US11793980B2 (en) * | 2019-08-31 | 2023-10-24 | Celero Systems, Inc. | Intestinal attachment device |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2021146296A1 (en) * | 2020-01-14 | 2021-07-22 | Rani Therapeutics, Llc | Swallowable devices for drug delivery in an intestinal tract |
| CA3170332A1 (en) * | 2020-02-18 | 2021-08-26 | Rani Therapeutics, Llc | Injection of a therapeutic formulation into a wall of the gastrointestinal tract |
| WO2021198353A1 (en) * | 2020-03-31 | 2021-10-07 | Danmarks Tekniske Universitet | A flexible foil for the delivery of therapeutic cargos |
| US20230240665A1 (en) * | 2020-06-29 | 2023-08-03 | The Governing Council Of The University Of Toronto | Magnetically actuated capsule |
| CN111772589B (zh) * | 2020-08-04 | 2022-07-12 | 重庆金山医疗技术研究院有限公司 | 一种判断胶囊内镜是否适用的检测系统及其探路胶囊 |
| CN113598690B (zh) * | 2021-08-10 | 2023-07-28 | 安徽光阵光电科技有限公司 | 一种用于人体体内医疗的内窥镜药丸 |
| EP4482559A1 (en) * | 2022-02-21 | 2025-01-01 | Rani Therapeutics, LLC | Devices, assemblies, and methods for delivering a fluid preparation into a gastrointestinal tract |
| CN119424884B (zh) * | 2024-09-29 | 2025-10-10 | 北京水木金昇医疗科技服务有限公司 | 一种递送注射药物的微针胶囊及其应用 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004504120A (ja) * | 2000-07-21 | 2004-02-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| JP2005021677A (ja) * | 2003-06-10 | 2005-01-27 | Medorekkusu:Kk | 経皮投薬用パッドベース、及び注射針 |
| JP2007007414A (ja) * | 2005-06-29 | 2007-01-18 | Lifescan Inc | 多区画配送システム |
| WO2007069696A1 (ja) * | 2005-12-16 | 2007-06-21 | Olympus Corporation | 被検体内導入装置および薬液吐出方法 |
| JP2007536377A (ja) * | 2004-05-03 | 2007-12-13 | イー−ピル ファーマ リミティド | 胃腸管における有効成分の送達 |
| WO2008040479A1 (de) * | 2006-10-07 | 2008-04-10 | Sanofi-Aventis Deutschland Gmbh | Optisches bestimmen der stopfenposition in glasampullen |
| JP2008532568A (ja) * | 2005-01-18 | 2008-08-21 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 電子制御されるカプセル |
| JP2008214333A (ja) * | 2006-12-26 | 2008-09-18 | Lifescan Inc | 血糖コントロールプロトコールを実行するシステムと方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474785A (en) * | 1990-01-24 | 1995-12-12 | Alza Corporation | Delivery system comprising means for controlling internal pressure |
| US5217449A (en) * | 1990-12-11 | 1993-06-08 | Miyarisan Kabushiki Kaisha | Medical capsule and apparatus for activating the same |
| DK42093D0 (da) | 1993-04-07 | 1993-04-07 | Bukh Meditec | Administrationsmetode |
| US6743211B1 (en) * | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| EP1200140A1 (en) | 1999-08-03 | 2002-05-02 | Smith & Nephew, Inc. | Controlled release implantable devices |
| US6478776B1 (en) | 2000-04-05 | 2002-11-12 | Biocardia, Inc. | Implant delivery catheter system and methods for its use |
| JP4643089B2 (ja) * | 2001-09-27 | 2011-03-02 | オリンパス株式会社 | カプセル型医療装置 |
| JP2002186672A (ja) * | 2001-09-28 | 2002-07-02 | Olympus Optical Co Ltd | 医療用カプセル装置 |
| FR2835730B1 (fr) * | 2002-02-11 | 2004-12-10 | C T M Ct De Transfert Des Micr | Dispositif pour la delivrance de substances et le prelevement intracorporel |
| WO2004000389A2 (en) | 2002-06-25 | 2003-12-31 | Sung-Yun Kwon | Rapidly dissolving micro-perforator for drug delivery and other applications |
| US7118531B2 (en) * | 2002-09-24 | 2006-10-10 | The Johns Hopkins University | Ingestible medical payload carrying capsule with wireless communication |
| AU2003288516A1 (en) * | 2002-12-26 | 2004-07-22 | Given Imaging Ltd. | Immobilizable in vivo sensing device |
| RU2334506C2 (ru) * | 2003-01-29 | 2008-09-27 | И-Пилл Фарма Лтд. | Активная доставка лекарственного средства в желудочно-кишечном тракте |
| US8000784B2 (en) * | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling device |
| DE102004026615A1 (de) † | 2004-06-01 | 2005-12-29 | Siemens Ag | Vorrichtung und Verfahren zur Freisetzung eines in das Körperinnere eines Patienten geführten therapeutischen Mittels |
| DE112005002806A5 (de) * | 2004-09-13 | 2007-08-30 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Verfahren zur Lagebestimmung bei einem EC-Motor |
| US20070265598A1 (en) * | 2004-09-30 | 2007-11-15 | Duocure, Inc. | Device and Method for Treating Weight Disorders |
| CN101184523B (zh) * | 2005-05-27 | 2011-04-13 | 奥林巴斯株式会社 | 被检体内导入装置 |
| US20070078414A1 (en) | 2005-08-05 | 2007-04-05 | Mcallister Devin V | Methods and devices for delivering agents across biological barriers |
| CA2635337C (en) | 2005-12-30 | 2015-02-17 | Nir Barak | Device for treating the anal sphincter |
| GB0603252D0 (en) * | 2006-02-17 | 2006-03-29 | Axcess Ltd | Dissolution aids for oral peptide delivery |
| US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
| EP2196131A4 (en) * | 2007-09-26 | 2012-12-05 | Olympus Medical Systems Corp | INTRODUCTION SYSTEM IN A SUBJECT |
| AU2010336330B2 (en) | 2009-12-24 | 2016-04-28 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
-
2010
- 2010-12-23 AU AU2010336330A patent/AU2010336330B2/en active Active
- 2010-12-23 DK DK20164025.7T patent/DK3756657T3/da active
- 2010-12-23 FI FIEP20164025.7T patent/FI3756657T3/fi active
- 2010-12-23 JP JP2012546244A patent/JP2013515576A/ja not_active Withdrawn
- 2010-12-23 DK DK18191328.6T patent/DK3461478T3/da active
- 2010-12-23 DK DK22166190.3T patent/DK4056173T3/da active
- 2010-12-23 CN CN201080064664.4A patent/CN102905753B/zh active Active
- 2010-12-23 PL PL20164025.7T patent/PL3756657T3/pl unknown
- 2010-12-23 EP EP22166190.3A patent/EP4056173B1/en active Active
- 2010-12-23 CA CA2785168A patent/CA2785168C/en active Active
- 2010-12-23 ES ES18191328T patent/ES2804716T3/es active Active
- 2010-12-23 PT PT201640257T patent/PT3756657T/pt unknown
- 2010-12-23 ES ES20164025T patent/ES3031275T3/es active Active
- 2010-12-23 EP EP18191328.6A patent/EP3461478B1/en not_active Revoked
- 2010-12-23 WO PCT/US2010/062070 patent/WO2011079302A2/en not_active Ceased
- 2010-12-23 EP EP20164025.7A patent/EP3756657B1/en active Active
- 2010-12-23 PL PL18191328T patent/PL3461478T3/pl unknown
- 2010-12-23 EP EP10840193.6A patent/EP2515992B2/en active Active
- 2010-12-23 CN CN201610322529.4A patent/CN105999526B/zh active Active
-
2015
- 2015-06-08 JP JP2015115816A patent/JP2015186590A/ja not_active Withdrawn
-
2016
- 2016-07-28 AU AU2016208382A patent/AU2016208382B2/en active Active
- 2016-10-04 JP JP2016196141A patent/JP6484208B2/ja active Active
-
2018
- 2018-03-14 JP JP2018046568A patent/JP2018110907A/ja not_active Withdrawn
- 2018-05-15 AU AU2018203418A patent/AU2018203418B2/en active Active
-
2020
- 2020-01-10 JP JP2020002601A patent/JP7590811B2/ja active Active
- 2020-05-08 AU AU2020203067A patent/AU2020203067B2/en active Active
-
2021
- 2021-04-22 JP JP2021072584A patent/JP7616937B2/ja active Active
-
2022
- 2022-11-04 AU AU2022263569A patent/AU2022263569B2/en not_active Expired - Fee Related
-
2023
- 2023-06-05 JP JP2023092726A patent/JP2023116591A/ja not_active Withdrawn
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004504120A (ja) * | 2000-07-21 | 2004-02-12 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| JP2005021677A (ja) * | 2003-06-10 | 2005-01-27 | Medorekkusu:Kk | 経皮投薬用パッドベース、及び注射針 |
| JP2007536377A (ja) * | 2004-05-03 | 2007-12-13 | イー−ピル ファーマ リミティド | 胃腸管における有効成分の送達 |
| JP2008532568A (ja) * | 2005-01-18 | 2008-08-21 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 電子制御されるカプセル |
| JP2007007414A (ja) * | 2005-06-29 | 2007-01-18 | Lifescan Inc | 多区画配送システム |
| WO2007069696A1 (ja) * | 2005-12-16 | 2007-06-21 | Olympus Corporation | 被検体内導入装置および薬液吐出方法 |
| WO2008040479A1 (de) * | 2006-10-07 | 2008-04-10 | Sanofi-Aventis Deutschland Gmbh | Optisches bestimmen der stopfenposition in glasampullen |
| JP2010505475A (ja) * | 2006-10-07 | 2010-02-25 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ガラス製アンプルのストッパ位置の光学的決定方法 |
| JP2008214333A (ja) * | 2006-12-26 | 2008-09-18 | Lifescan Inc | 血糖コントロールプロトコールを実行するシステムと方法 |
Cited By (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013522194A (ja) * | 2010-03-10 | 2013-06-13 | インキューブ ラブズ， エルエルシー | 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物 |
| JP2016529066A (ja) * | 2013-09-05 | 2016-09-23 | ヴェリリー ライフ サイエンシズ エルエルシー | 機能化粒子の送達 |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| US11291709B2 (en) | 2014-05-15 | 2022-04-05 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising TNF-inhibiting antibodies |
| US11304993B2 (en) | 2014-05-15 | 2022-04-19 | Rani Therapeutics, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| JP7558326B2 (ja) | 2014-05-15 | 2024-09-30 | ラニ セラピューティクス， エルエルシー | 自己免疫疾患および／または炎症性状態を処置するための医薬品の製造における抗インターロイキン抗体（ａｉ抗体）の使用 |
| US12018090B2 (en) | 2014-05-15 | 2024-06-25 | Rani Therapeutics, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| JP2017521479A (ja) * | 2014-05-15 | 2017-08-03 | ラニ セラピューティクス， エルエルシー | ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法 |
| JP2023068091A (ja) * | 2014-05-15 | 2023-05-16 | ラニ セラピューティクス， エルエルシー | 自己免疫疾患および／または炎症性状態を処置するための医薬品の製造における抗インターロイキン抗体（ａｉ抗体）の使用 |
| US11026998B2 (en) | 2014-05-15 | 2021-06-08 | Rani Therapeutics, Llc | Shaped mass composition comprising exenatide |
| US10953075B2 (en) | 2014-05-15 | 2021-03-23 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising anti-interleukin antibodies |
| JP2021042239A (ja) * | 2015-05-08 | 2021-03-18 | インキューブ ラブズ， エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤 |
| JP2018520995A (ja) * | 2015-05-08 | 2018-08-02 | インキューブ ラブズ， エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤 |
| JP7232805B2 (ja) | 2015-05-08 | 2023-03-03 | ラニ セラピューティクス， エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤 |
| JP7185401B2 (ja) | 2015-05-08 | 2022-12-07 | ラニ セラピューティクス， エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のための抗インターロイキン抗体製剤 |
| JP2021169530A (ja) * | 2015-09-08 | 2021-10-28 | インキューブ ラブズ， エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤 |
| JP2018526403A (ja) * | 2015-09-08 | 2018-09-13 | インキューブ ラブズ， エルエルシー | 嚥下可能な薬物送達デバイスを使用する腸管の管腔中への送達のためのｐｃｓｋ９抗体製剤 |
| JP7295811B2 (ja) | 2017-05-17 | 2023-06-21 | マサチューセッツ インスティテュート オブ テクノロジー | 自己作動物品 |
| US12036324B2 (en) | 2017-05-17 | 2024-07-16 | Massachusetts Institute Of Technology | Self-righting systems and related components and methods |
| JP7044805B2 (ja) | 2017-05-17 | 2022-03-30 | マサチューセッツ インスティテュート オブ テクノロジー | 組織繋留物品 |
| JP7045397B2 (ja) | 2017-05-17 | 2022-03-31 | マサチューセッツ インスティテュート オブ テクノロジー | 自己復元システムおよび関連構成要素 |
| JP2020520700A (ja) * | 2017-05-17 | 2020-07-16 | マサチューセッツ インスティテュート オブ テクノロジー | 自己復元システムならびに関連構成要素および方法 |
| JP7550201B2 (ja) | 2017-05-17 | 2024-09-12 | マサチューセッツ インスティテュート オブ テクノロジー | 自己復元システムならびに関連構成要素および方法 |
| JP7038739B2 (ja) | 2017-05-17 | 2022-03-18 | マサチューセッツ インスティテュート オブ テクノロジー | 自己復元物品 |
| US11369574B2 (en) | 2017-05-17 | 2022-06-28 | Massachusetts Institute Of Technology | Self-righting systems and related components and methods |
| JP2020520915A (ja) * | 2017-05-17 | 2020-07-16 | マサチューセッツ インスティテュート オブ テクノロジー | 自己復元システム、方法、および関連構成要素 |
| JP2020520907A (ja) * | 2017-05-17 | 2020-07-16 | マサチューセッツ インスティテュート オブ テクノロジー | 組織繋留物品 |
| JP2020520914A (ja) * | 2017-05-17 | 2020-07-16 | マサチューセッツ インスティテュート オブ テクノロジー | 自己復元物品 |
| US11607390B2 (en) | 2017-05-17 | 2023-03-21 | Massachusetts Institute Of Technology | Self-righting systems and related components and methods |
| JP2023036588A (ja) * | 2017-05-17 | 2023-03-14 | マサチューセッツ インスティテュート オブ テクノロジー | 自己復元システムならびに関連構成要素および方法 |
| JP7219723B2 (ja) | 2017-05-17 | 2023-02-08 | マサチューセッツ インスティテュート オブ テクノロジー | 自己復元システムならびに関連構成要素および方法 |
| JP2020521534A (ja) * | 2017-05-17 | 2020-07-27 | マサチューセッツ インスティテュート オブ テクノロジー | 自己作動物品 |
| CN112867483B (zh) * | 2018-08-14 | 2023-03-21 | 阿尔玛疗法有限公司 | 可膨胀的药物递送丸剂 |
| CN112867483A (zh) * | 2018-08-14 | 2021-05-28 | 阿尔玛疗法有限公司 | 可膨胀的药物递送丸剂 |
| JP2021534145A (ja) * | 2018-08-14 | 2021-12-09 | アルマ セラピューティクス リミテッド | 膨張可能な薬物送達ピル |
| JP7344277B2 (ja) | 2018-08-14 | 2023-09-13 | アルマ セラピューティクス リミテッド | 膨張可能な薬物送達ピル |
| JP2024107367A (ja) * | 2018-08-15 | 2024-08-08 | リンドラ セラピューティクス， インコーポレイティド | 治療薬物の腸内送達のためのシステム |
| JP2021535090A (ja) * | 2018-08-15 | 2021-12-16 | リンドラ セラピューティクス， インコーポレイティド | 治療薬物の腸内送達のためのシステム |
| JP7334242B2 (ja) | 2018-09-25 | 2023-08-28 | ラニ セラピューティクス， エルエルシー | 拡張可能なエンクロージャを備えた摂取可能なデバイス |
| JP2022502383A (ja) * | 2018-09-25 | 2022-01-11 | ラニ セラピューティクス， エルエルシー | 拡張可能なエンクロージャを備えた摂取可能なデバイス |
| US12121688B2 (en) | 2019-02-01 | 2024-10-22 | Novo Nordisk A/S | Medical device with actuation mechanism |
| US11771829B2 (en) | 2019-02-01 | 2023-10-03 | Massachusetts Institute Of Technology | Systems and methods for liquid injection |
| JP7465886B2 (ja) | 2019-03-01 | 2024-04-11 | ラニ セラピューティクス， エルエルシー | 治療剤を胃壁の中に送達するためのデバイス、システム、および方法 |
| JP2022523532A (ja) * | 2019-03-01 | 2022-04-25 | ラニ セラピューティクス， エルエルシー | 治療剤を胃壁の中に送達するためのデバイス、システム、および方法 |
| JP7539416B2 (ja) | 2019-06-07 | 2024-08-23 | ノボ・ノルデイスク・エー／エス | 送達部材取り外しを有する摂取可能な装置 |
| JP2022535297A (ja) * | 2019-06-07 | 2022-08-05 | ノボ・ノルデイスク・エー／エス | 送達部材取り外しを有する摂取可能な装置 |
| JP2022552829A (ja) * | 2019-10-08 | 2022-12-20 | インキューブ ラブズ， エルエルシー | 徐放性製剤送達デバイス |
| JP2025081392A (ja) * | 2020-09-16 | 2025-05-27 | イーライ リリー アンド カンパニー | 拡張アームを有する経口薬物送達デバイス |
| JP7784014B2 (ja) | 2020-09-16 | 2025-12-10 | イーライ リリー アンド カンパニー | 拡張アームを有する経口薬物送達デバイス |
| WO2023002270A1 (en) * | 2021-07-19 | 2023-01-26 | Cochlear Limited | Self-propelled pharmaceutical delivery capsules |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7616937B2 (ja) | 嚥下可能薬物送達デバイスおよび薬物送達方法 | |
| US12268831B2 (en) | Swallowable drug delivery device and methods of drug delivery | |
| HK40044998A (en) | Swallowable drug delivery device | |
| HK40077106A (en) | Swallowable drug delivery device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131226 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141009 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141016 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150113 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150608 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150810 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20150812 |